CBUS
Cibus, Inc.
Biotechnology · Healthcare · United States
1.29
close · 2026-10-30
value
3
cheaper than peers3
quality
11
stronger fundamentals11
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 23.00× | 32 |
| cash flow yield, 3 years ago | -21.2% | 29 |
| price to book | 6.65× | 28 |
| cash flow yield, 2 years ago | -51.3% | 19 |
| cash flow yield, latest year | -51.9% | 17 |
| cash flow yield, 1 year ago | -59.7% | 13 |
| earnings yield, latest year | -215.5% | 4 |
| earnings yield, 1 year ago | -839.5% | 1 |
8 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 62.6% | 71 |
| operating margin | -721.0% | 27 |
| return on equity | -190.1% | 11 |
| debt to equity | 778.3% | 4 |
4 of 4 measures available
Facts
| market cap | $99M |
| free cash flow | -$52.7M |
| employees | 118 |
| first trade | 2017-07-20 |
| next earnings | 2026-11-12 |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.78 | -10.83 | -25.95 | -18.50 |
| free cash flow | -$51.2M | -$58.9M | -$50.5M | -$20.9M |
| net income | -$127.1M | -$251.4M | -$267.6M | -$16.9M |
| revenue | $3.6M | $4.3M | $1.8M | $157,000 |
| unusual items | -$30.1M | -$181.4M | -$249.4M | $0 |